HC Wainwright Predicts Weaker Earnings for Hoth Therapeutics

Hoth Therapeutics, Inc. (NASDAQ:HOTH) – Equities research analysts at HC Wainwright lowered their FY2024 earnings per share estimates for Hoth Therapeutics in a research note issued to investors on Thursday, January 23rd. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($1.36) per share for the year, down from their prior forecast of ($1.18). HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Hoth Therapeutics’ current full-year earnings is ($1.18) per share. HC Wainwright also issued estimates for Hoth Therapeutics’ Q4 2024 earnings at ($0.39) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.27) EPS, Q3 2025 earnings at ($0.23) EPS, Q4 2025 earnings at ($0.18) EPS and FY2025 earnings at ($0.97) EPS.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01).

Other research analysts have also recently issued research reports about the stock. Benchmark restated a “speculative buy” rating and set a $3.00 price target on shares of Hoth Therapeutics in a research note on Friday, October 11th. D. Boral Capital restated a “buy” rating and set a $5.00 target price on shares of Hoth Therapeutics in a research report on Tuesday, January 7th.

Hoth Therapeutics Stock Up 5.7 %

HOTH stock opened at $1.29 on Monday. Hoth Therapeutics has a twelve month low of $0.58 and a twelve month high of $3.80. The company has a market cap of $8.90 million, a PE ratio of -0.98 and a beta of 0.75. The business’s 50-day simple moving average is $1.06 and its 200 day simple moving average is $0.92.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC bought a new position in Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.